About: Association of Renin Angiotensin System Blockers with Outcomes in Patients with Covid-19: A Systematic Review and Meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Association of Renin Angiotensin System Blockers with Outcomes in Patients with Covid-19: A Systematic Review and Meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Association of Renin Angiotensin System Blockers with Outcomes in Patients with Covid-19: A Systematic Review and Meta-analysis
Creator	Fiorello, Brittany Garg, Aakash Kostis, John Rout, Amit Sharma, Abhishek
Source	MedRxiv
abstract	Background: Patients with cardiovascular disease are at increased risk of critical illness and mortality from Covid-19 disease. Conflicting findings have raised concerns regarding the association of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) use with likelihood or severity of infection during this pandemic. Objective: To study the cumulative evidence for association of ACEI/ARB use with outcomes among patients with confirmed Covid-19. Methods: The MEDLINE and EMBASE databases were thoroughly searched from November 01, 2019 to May 15, 2020 for studies reporting on outcomes based on ACEI/ARB use in patients with confirmed Covid-19. Preferred reporting items for systematic review and meta-analysis guidelines were used for the present study. Relevant data was collected and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using random-effects model. Main Outcome measures: In-hospital mortality was the primary end of interest. Second end-point was severe or critical illness defined as either need for intensive care unit, invasive mechanical ventilation, or mortality. Results: Fifteen studies with total of 23,822 patients (N ACEI/ARB=6,650) were included in the present analysis. Overall, prevalence of ACEI/ARB use ranged from 7.7% to 46.2% across studies. Among 10 studies, patients using ACEI/ARB had similar odds of mortality [OR 1.03 (0.69-1.55)] and severe or critical illness [1.18 (0.91-1.54)] compared to those not on ACEI/ARB. In an analysis restricted to patients with hypertension, ACEI/ARB use was associated with significantly lower mortality [0.64 (0.45-0.89)], while the odds of severe/critical illness [0.76(0.52-1.12); p=0.16] remained non-significant compared with non-ACEI/ARB users. Conclusion: There is no evidence for increased risk of severe illness or mortality in patients using ACEI/ARB compared with non-users. In patients with hypertension, ACE/ARB use might be associated with reduced mortality, however these findings need to be confirmed in prospective randomized controlled trials.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.23.20111401
has license	medrxiv
sha1sum (hex)	0d1b56c027922b135f6f1eca7883879838a193eb
schema:url	https://doi.org/10.1101/2020.05.23.20111401
resource representing a document's title	Association of Renin Angiotensin System Blockers with Outcomes in Patients with Covid-19: A Systematic Review and Meta-analysis
resource representing a document's body	covid:0d1b56c027922b135f6f1eca7883879838a193eb#body_text
is schema:about of	named entity 'converting' named entity 'Outcomes' named entity 'CONFLICTING' named entity 'USE' named entity 'BACKGROUND' named entity 'receptor' named entity 'infection' named entity 'likelihood' named entity 'inhibitors' named entity 'Patients' named entity 'Angiotensin' named entity 'ARBs' named entity 'Systematic Review' named entity 'ARBs' named entity 'SARS-CoV-2' named entity 'viral load' named entity 'medRxiv' named entity 'angiotensin' named entity 'RAS' named entity 'SARS-Cov-2' named entity 'ACEI' named entity 'medRxiv' named entity 'ACEI' named entity 'ACE2' named entity 'retrospective studies' named entity 'myocardial injury' named entity 'ACEI' named entity 'ACEI' named entity 'ACEI' named entity 'RAS' named entity 'Covid-19' named entity 'Covid-19' named entity 'Covid-19' named entity 'ACE inhibitors' named entity 'ACEI' named entity 'ARBs' named entity 'Coronavirus 2019' named entity 'control groups' named entity 'CC-BY-ND' named entity 'Covid' named entity 'medRxiv' named entity 'Covid' named entity 'peer review' named entity 'infection' named entity 'SARS-Cov-2' named entity 'CC-BY-ND' named entity 'prothrombotic' named entity 'medRxiv' named entity 'endothelial dysfunction' named entity 'ACEI' named entity 'immune dysregulation' named entity 'ARBs' named entity 'Covid-19' named entity 'medRxiv' named entity 'lung' named entity 'peer-reviewed' named entity 'CC-BY-ND' named entity '3, 4' named entity 'ACE2' named entity 'RCTs' named entity 'peer review' named entity 'meta-analysis' named entity 'odds ratios' named entity 'ACE2' named entity 'ACEI' named entity 'ACEI' named entity 'statistical analysis' named entity 'RAS' named entity 'Covid' named entity 'anti-hypertensive' named entity 'medRxiv' named entity 'confounding variables' named entity 'angiotensin II' named entity 'angiotensin' named entity 'Angiotensin receptor blockers' named entity 'ACEI' named entity 'cardiovascular' named entity 'morbidity' named entity 'CC-BY-ND' named entity 'lung' named entity 'Cochrane'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software